dr. robert on next steps following the phase iii combi-v study in melanoma
Published 7 years ago • 136 plays • Length 1:33Download video MP4
Download video MP3
Similar videos
-
1:40
dr. robert on the phase iii combi-v study in braf-mutant melanoma
-
2:12
phase iii combi-d study of dabrafenib and trametinib in patients with melanoma
-
1:19
dr. robert on potential of dabrafenib/trametinib in melanoma brain metastases
-
2:19
dr. robert on 5-year analysis of dabrafenib/trametinib in braf v600-mutant melanoma
-
1:42
dr. jason luke describes results from the phase iii combi-d trial
-
2:33
dr. sullivan discusses role of dabrafenib plus trametinib in melanoma
-
0:30
dr. postow on fda approval of adjuvant dabrafenib plus trametinib in braf-mutant melanoma
-
4:12
adjuvant therapy in melanoma: combi-ad trial
-
1:17
dr. dummer on combi-ad trial results in braf-mutant melanoma
-
2:11
dr. keith t. flaherty on 3-year follow-up of combi-d in metastatic melanoma
-
5:05
dabrafenib plus trametinib preferable to vemurafenib alone in melanoma
-
8:48
combi-ad: dual-targeted therapy for stage 3 melanoma
-
1:36
dr. caroline robert discusses the mek inhibitor trametinib metric trial results
-
1:04
dr. wilson on long-term data with dabrafenib plus trametinib in melanoma
-
2:31
neoadjuvant therapy with trametinib and dabrafenib in high risk resectable braf-mutant melanoma
-
3:06
combi-d: phase 3 trial of dabrafenib plus trametinib in braf v600e/k-mutated melanoma
-
22:44
braf targeted therapy - melanoma education symposium, peter boasberg md
-
4:45
combi-ad trial: adjuvant dabrafenib plus trametinib in patients with resected stage iii braf v60...
-
3:02
a new standard for stage 3 braf melanoma